Potential Anabolic Effects of Androgens on Bone

Mayo Clinic Proceedings

Volumn 79, Issue 4 SUPPL., 2004, Pages

  Kearns, Ann E ^a   Khosla, Sundeep ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIONE; CONJUGATED ESTROGEN; ESTERIFIED ESTROGEN; ESTRADIOL; ESTRATEST; ESTROGEN; ESTROGEN DERIVATIVE; ESTRONE; METHYLTESTOSTERONE; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; BODY COMPOSITION; BONE DENSITY; BONE GROWTH; BONE METABOLISM; BONE MINERAL; ESTROGEN DEFICIENCY; HUMAN; MENOPAUSE; NONHUMAN; OSTEOLYSIS; PREMENOPAUSE; REVIEW;

EID: 1642564265     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(19)30667-6     Document Type: Review

References (46)

1. Hofbauer LC, Khosla S. Androgen effects on bone metabolism: recent progress and controversies. Eur J Endocrinol. 1999;140:271-286.
2. Liegibel UM, Sommer U, Tomakidi P, et al. Concerted action of androgens and mechanical strain shifts bone metabolism from high turnover into an osteoanabolic mode. J Exp Med. 2002;196:1387-1392.
3. Ehrlich PJ, Noble BS, Jessop HL, Stevens HY, Mosley JR, Lanyon LE. The effect of in vivo mechanical loading on estrogen receptor alpha expression in rat ulnar osteocytes. J Bone Miner Res. 2002;17:1646-1655.
4. Lee K, Jessop H, Suswillo R, Zaman G, Lanyon L. Endocrinology: bone adaptation requires oestrogen receptor-α. Nature. 2003;424:389.
5. Vanderschueren D, Van Herck E, Suiker AM, et al. Bone and mineral metabolism in the androgen-resistant (testicular feminized) male rat. J Bone Miner Res. 1993;8:801-809.
6. Turner RT, Wakley GK, Hannon KS. Differential effects of androgens on cortical bone histomorphometry in gonadectomized male and female rats. J Orthop Res. 1990;8:612-617.
7. Kawano H, Sato T, Yamada T, et al. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A. 2003;100:9416-9421.
8. Gallagher AC, Chambers TJ, Tobias JH. Androgens contribute to the stimulation of cancellous bone formation by ovarian hormones in female rats. Am J Physiol. 1996;270(3, pt 1):E407-E412.
9. Mason RA, Morris HA. Effects of dihydrotestosterone on bone biochemical markers in sham and oophorectomized rats. J Bone Miner Res. 1997;12:1431-1437.
10. Tobias JH, Gallagher A, Chambers TJ. 5α-Dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats. Am J Physiol. 1994;267(6, pt 1):E853-E859.
11. Coxam V, Bowman BM, Mecham M, Roth CM, Miller MA, Miller SC. Effects of dihydrotestosterone alone and combined with estrogen on bone mineral density, bone growth, and formation rates in ovariectomized rats. Bone. 1996;19:107-114.
12. Turner RT, Lifrak ET, Beckner M, Wakley GK, Hannon KS, Parker LN. Dehydroepiandrosterone reduces cancellous bone osteopenia in ovariectomized rats. Am J Physiol. 1990;258(4, pt 1):E673-E677.
13. Lea CK, Flanagan AM. Ovarian androgens protect against bone loss in rats made oestrogen deficient by treatment with ICI 182,780. J Endocrinol. 1999;160:111-117.
14. Lundon K, Dumitriu M, Grynpas MD. Supraphysiologic levels of testosterone affect cancellous and cortical bone in the young female cynomolgus monkey. Calcif Tissue Int. 1997;60:54-62.
15. Lundon KM, Jayo MJ, Register TC, Dumitriu M, Grynpas MD. The effect of androstenedione/estrone supplementation on cortical and cancellous bone in the young intact female monkey: a model for the effects of polycystic ovarian disease on the skeleton? Osteoporos Int. 2000;11:778-789.
16. Marcus R, Leary D, Schneider DL, Shane E, Favus M, Quigley CA. The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome. J Clin Endocrinol Metab. 2000;85:1032-1037.
17. Good C, Tulchinsky M, Mauger D, Demers LM, Legro RS. Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil Steril. 1999;72:21-25.
18. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod. 2001;16:1255-1260.
19. Dixon JE, Rodin A, Murby B, Chapman MG, Fogelman I. Bone mass in hirsute women with androgen excess. Clin Endocrinol (Oxf). 1989;30:271-277.
20. Prezelj J, Kocijancic A. Bone mineral density in hyperandrogenic amenorrhea. Calcif Tissue Int. 1993;52:422-424.
21. Douchi T, Oki T, Yamasaki H, Kuwahata R, Nakae M, Nagata Y. Relationship of androgens to muscle size and bone mineral density in women with polycystic ovary syndrome. Obstet Gynecol. 2001;98:445-449.
22. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab. 2002;87:1509-1516.
23. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turn-over markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83:2266-2274.
24. Buchanan JR, Myers C, Lloyd T, Leuenberger P, Demers LM. Determinants of peak trabecular bone density in women: the role of androgens, estrogen, and exercise. J Bone Miner Res. 1988;3:673-680.
25. Buchanan JR, Hospodar P, Myers C, Leuenberger P, Demers LM. Effect of excess endogenous androgens on bone density in young women. J Clin Endocrinol Metab. 1988;67:937-943.
26. Slemenda C, Longcope C, Peacock M, Hui S, Johnston CC. Sex steroids, bone mass, and bone loss: a prospective study of pre-, peri-, and postmenopausal women. J Clin Invest. 1996;97:14-21.
27. Sowers M, Willing M, Burns T, et al. Genetic markers, bone mineral density, and serum osteocalcin levels. J Bone Miner Res. 1999;14:1411-1419.
28. Westberg L, Baghaei F, Rosmond R, et al. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab. 2001;86:2562-2568.
29. Duncan EL, Brown MA, Sinsheimer J, et al. Suggestive linkage of the parathyroid receptor type 1 to osteoporosis. J Bone Miner Res. 1999;14:1993-1999.
30. Salmen T, Heikkinen AM, Mahonen A, et al. Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial. J Bone Miner Res. 2003;18:319-324.
31. Steinberg KK, Freni-Titulaer LW, DePuey EG, et al. Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab. 1989;69:533-539.
32. Stone K, Bauer DC, Black DM, Sklarin P, Ensrud KE, Cummings SR, Study of Osteoporotic Fractures Research Group. Hormonal predictors of bone loss in elderly women: a prospective study. J Bone Miner Res. 1998;13:1167-1174.
33. Cummings SR, Browner WS, Bauer D, et al, Study of Osteoporotic Fractures Research Group. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med. 1998;339:733-738.
34. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res. 1997;12:1833-1843.
35. Melton LJ III, Khosla S, Malkasian GD, Achenbach SJ, Oberg AL, Riggs BL. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res. 2003;18:900-905.
36. Davidson BJ, Riggs BL, Wahner HW, Judd HL. Endogenous cortisol and sex steroids in patients with osteoporotic spinal fractures. Obstet Gynecol. 1983;61:275-278.
37. Manolagas SC, Anderson DC, Lindsay R. Adrenal steroids and the development of osteoporosis in oophorectomised women. Lancet. 1979;2:597-600.
38. Szathmari M, Szucs J, Feher T, Hollo I. Dehydroepiandrosterone sulphate and bone mineral density. Osteoporos Int. 1994;4:84-88.
39. Rozenberg S, Ham H, Bosson D, Peretz A, Robyn C. Age, steroids and bone mineral content. Maturitas. 1990;12:137-143.
40. Barrett-Connor E, Kritz-Silverstein D, Edelstein SL. A prospective study of dehydroepiandrosterone sulfate (DHEAS) and bone mineral density in older men and women. Am J Epidemiol. 1993;137:201-206.
41. Devogelaer JP, Crabbe J, Nagant de Deuxchaisnes C. Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. Br Med J (Clin Res Ed). 1987;294:798-800.
42. Raisz LG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab. 1996;81:37-43.
43. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause [published correction appears in Obstet Gynecol. 1995;85(5, pt 1):668]. Obstet Gynecol. 1995;85:529-537.
44. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause [published correction appears in Obstet Gynecol. 1995;85(5, pt 1):668]. Obstet Gynecol. 1995;85:529-537.
45. Barrett-Connor E, Young R, Notelovitz M, et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women: effects on bone mineral density, symptoms and lipid profiles. J Reprod Med. 1999;44:1012-1020.
46. Labrie F, Diamond P, Cusan L, Gomez JL, Belanger A, Candas B. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab. 1997;82:3498-3505.